Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Purchased by Barclays PLC

Barclays PLC grew its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 128.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 154,297 shares of the biopharmaceutical company’s stock after acquiring an additional 86,677 shares during the quarter. Barclays PLC owned about 0.26% of Vanda Pharmaceuticals worth $722,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of VNDA. Nantahala Capital Management LLC boosted its holdings in shares of Vanda Pharmaceuticals by 57.3% in the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock valued at $9,003,000 after acquiring an additional 580,265 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Vanda Pharmaceuticals by 17.0% in the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock valued at $11,379,000 after acquiring an additional 292,172 shares during the period. Massachusetts Financial Services Co. MA acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at approximately $864,000. Geode Capital Management LLC boosted its holdings in shares of Vanda Pharmaceuticals by 7.1% in the third quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company’s stock valued at $6,689,000 after acquiring an additional 94,870 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Vanda Pharmaceuticals by 1,184.6% in the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 57,393 shares during the period. 88.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

VNDA has been the subject of several research analyst reports. StockNews.com initiated coverage on Vanda Pharmaceuticals in a report on Sunday. They issued a “hold” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Vanda Pharmaceuticals in a report on Monday, December 23rd.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ VNDA opened at $4.45 on Thursday. The stock has a fifty day moving average price of $4.86 and a 200 day moving average price of $5.05. Vanda Pharmaceuticals Inc. has a 1-year low of $3.46 and a 1-year high of $6.75. The company has a market cap of $259.47 million, a PE ratio of -15.89 and a beta of 0.77.

Insider Buying and Selling

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the transaction, the director now owns 44,857 shares in the company, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 8.90% of the company’s stock.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.